ReviewFrontiers in oncology2025
A case of high-grade adenosquamous carcinoma of the breast: case report and literature review.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade adenosquamous carcinoma (HGASC) is a rare and aggressive subtype of metaplastic breast cancer (MpBC). This article reports a case of HGASC (pT2N0M0 Stage IIA) in a 43-year-old female and reviews the relevant literature, with a specific focus on distinguishing HGASC from other MpBC subtypes, particularly low-grade adenosquamous carcinoma (LGASC). The patient underwent a skin-sparing mastectomy with abdominal rectus myocutaneous flap reconstruction. Histopathology confirmed HGASC with metaplastic features. Postoperative adjuvant chemotherapy with capecitabine was administered. The case highlights the unique clinical, imaging, and pathological characteristics of HGASC, its therapeutic challenges, and the need for individualized treatment strategies. A five-month follow-up showed no signs of recurrence or metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.